Evidence map›Paper›PMID 41321024›Full record

ArticleClinical and molecular hepatology2026

Hypothyroidism and the risk of liver-related events in patients with metabolic dysfunction-associated steatotic liver disease.

Xinrui Jin, Sherlot Juan Song, Jimmy Che-To Lai, Grace Lai-Hung Wong, Alice Pik-Shan Kong, Nana Peng, Xiang Xiao, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip

Abstract read
In one paragraph

Article in Clinical and molecular hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Xinrui JinDepartment of Medicine and Therapeutics, The Chinese University of Hong Kong, China.
Sherlot Juan SongDepartment of Medicine and Therapeutics, The Chinese University of Hong Kong, China.
Jimmy Che-To LaiDepartment of Medicine and Therapeutics, The Chinese University of Hong Kong, China.
Grace Lai-Hung WongDepartment of Medicine and Therapeutics, The Chinese University of Hong Kong, China.
Alice Pik-Shan KongDepartment of Medicine and Therapeutics, The Chinese University of Hong Kong, China.
Nana PengDepartment of Medicine and Therapeutics, The Chinese University of Hong Kong, China.
Xiang XiaoDepartment of Medicine and Therapeutics, The Chinese University of Hong Kong, China.
Vincent Wai-Sun WongDepartment of Medicine and Therapeutics, The Chinese University of Hong Kong, China.
Terry Cheuk-Fung YipDepartment of Medicine and Therapeutics, The Chinese University of Hong Kong, China.

Funding

AbbottAstra ZenecaBayerBoehringer IngelheimDexcomEli-LillyGilead SciencesHKSAR 14106923Illuminatio Medical TechnologyKyowa KirinMerck SeronoMerck Sharp and DohmeNestleNovoNordiskPfizerSanofiZuellig Pharma
6 · The paper itself

Abstract

BACKGROUND/

aimsPrevious studies suggest that hypothyroidism is associated with metabolic dysfunction-associated steatotic liver disease (MASLD) and its histological severity, but clinical outcome data are largely lacking. We aimed to study the impact of hypothyroidism on liver-related events (LREs).

methodsPatients with MASLD were identified from a territory-wide registry in Hong Kong during 2000-2024. Thyroid status was determined using diagnosis codes and thyroid function tests. The primary outcome, LRE, was defined as a composite of hepatic decompensation, hepatocellular carcinoma, liver transplantation, and liver-related death.

resultsA total of 20,478 patients with MASLD were included in the final analysis (mean age 56.4±13.2 years; 43.9% male). At baseline, 18,178 (88.8%) patients were euthyroid, 598 (2.9%) were hyperthyroid, and 1,702 (8.3%) were hypothyroid. Compared with euthyroid patients, both hyperthyroidism and overt hypothyroidism were associated with cirrhosis. At a median follow-up of 4.8 years, 179 patients developed LREs, and 26 died from liver disease. Compared with patients with normal serum thyroid-stimulating hormone (TSH) levels of 0.4-4 mIU/L, those with subclinical (4-10 mIU/L; adjusted time-dependent cause-specific hazard ratio [aCSHR], 2.49; 95% CI, 1.51-4.13) and overt hypothyroidism (>10 mIU/L; aCSHR, 4.91; 95% CI, 1.56-15.47) had an increased risk of LREs. Time-dependent, but not baseline, TSH and thyroid status were associated with LRE risk.

conclusionsSubclinical and overt hypothyroidism are associated with an increased risk of LREs in a dose-dependent manner. The association with time-dependent but not baseline thyroid status underscores the importance of thyroid monitoring and suggests that correction of hypothyroidism may mitigate LRE risk.

Indexed as

Fatty LiverHypothyroidismAdultAgedCarcinoma, HepatocellularFemaleHong KongHumansLiver CirrhosisLiver NeoplasmsLiver TransplantationMaleMiddle AgedProportional Hazards ModelsRegistriesRisk FactorsThyrotropinCirrhosisFatty liverHepatocellular carcinomaSubclinical hypothyroidismThyroid function test

Identifiers

PMID41321024
PMCPMC12835781

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.